AMP analog / AMPK activator (research)
AICAR
Converted to ZMP, an AMP mimetic that activates and exercise-mimetic metabolic programmes in experimental systems.
Primary Mechanism of Action
Clinical / Scientific
AICAR is phosphorylated to ZMP, which mimics AMP at ’s gamma subunit, activating independently of a large drop in cellular ATP. Downstream effects include fatty-acid oxidation and GLUT4-related glucose uptake in muscle models.
Pathway Targets
AMPK
Scientific explanation
Direct pharmacological activation via ZMP.
GLUT4 / glucose uptake
Scientific explanation
Downstream metabolic effect in muscle models.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: AMPK → GLUT4 / glucose uptake
Mechanistically Relevant Repurposed & Adjunctive Applications
Experimental AMPK agonism
PreclinicalMechanistic rationale
Classic research tool for . Not an approved exercise-mimetic medicine in ordinary practice.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| AMPK | Activation (ZMP) | Exercise-mimetic metabolism | Established mechanism (experimental pharmacology) |
In Plain Language
AICAR is turned into a look-alike of AMP, the cell’s “energy is low” signal, which switches on .
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Oncology Mechanistic Relevance
Cancers in the atlas where this compound has a mapped mechanistic rationale. Evidence tiers are not equivalent and do not imply treatment.
Pharmacologic activation is a research tool.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.